Prognostic role of long noncoding RNA CASC11 in cancer patients: A meta-analysis
2024

The Role of CASC11 in Cancer Prognosis

Sample size: 660 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhang Song, Xu Bo, Zhang Ji-Ling, Liu Shun-Hai, Xiang Xin, Liu Pan

Primary Institution: The Fourth People’s Hospital of Neijiang, Sichuan, China

Hypothesis

Does the expression of long noncoding RNA CASC11 correlate with cancer prognosis?

Conclusion

CASC11 expression is significantly associated with poor overall survival in cancer patients, suggesting it could be a valuable prognostic marker.

Supporting Evidence

  • The overexpression of CASC11 was significantly associated with poor overall survival.
  • High levels of CASC11 expression predicted worse clinical staging and distant metastasis.
  • Subgroup analysis showed consistent results across different cancer types.

Takeaway

CASC11 is a type of RNA that doesn't make proteins but helps cancer grow. If there's a lot of it, it usually means the cancer is worse.

Methodology

A meta-analysis of 11 studies examining the relationship between CASC11 expression and cancer prognosis using pooled hazard ratios and odds ratios.

Potential Biases

Potential bias due to the limited geographic diversity of the sample and reliance on published data.

Limitations

The study included only Chinese patients, had a small number of reports, and relied on data extraction from survival curves, which may introduce errors.

Participant Demographics

All participants were cancer patients from China, with various types of malignancies.

Statistical Information

P-Value

0.00001

Confidence Interval

95%CI = 1.64–2.60

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1097/MD.0000000000040823

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication